Minicircle is a method development company that has developed and seeks to commercialize the world’s first reversible human genetic enhancement platform, using highly expressive DNA plasmids to add genes to the human body without altering your pre-existing genome. Our reversible plasmid platform is completely non-inflammatory (unlike AAV) and non-heritable. It is designed as a universal gene therapy protocol. Minicircle makes gene therapy fast, safe, and easy to use.

In Vivo Frontiers: The Promise and Progress of RNA Delivery & Gene Editing brought together leading researchers in RNA delivery and gene editing to discuss the latest advancements and challenges in these two fields.

Website: https://innovations.stanford.edu/in-v...

Follow us on social
LinkedIn:   / stanford-healthcare-innovation-lab  
Twitter: @StanfordHIL
Instagram: @StanfordSHIL